DanaherFRA:DAP -1.20%72 Days Payable is 69.80 as of Mar. 2026, which is 1% above its 10-year median of 69.44. GuruFocus rates FRA:DAP with a GF Score™ of 72/100 and a GF Value™ of €204.24 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Danaher ranks worse than 52.63% on this metric.
Danaher's average Accounts Payable for the
three
months ended in Mar. 2026 was €1,562 Mil. Danaher's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €2,041 Mil.
Hence, Danaher's Days Payable for the
three
months ended in Mar. 2026 was 69.80.
The historical rank and industry rank for Danaher's Days Payable or its related term are showing as below:
FRA:DAP'
s Days Payable Range Over the Past 10 Years
Min: 62.98 Med: 69.44 Max: 88.13
Current: 62.98
During the past 13 years, Danaher's highest Days Payable was 88.13. The lowest was 62.98. And the median was 69.44.
FRA:DAP's Days Payable is ranked worse than 52.63% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs FRA:DAP: 62.98
Danaher's Days Payable
declined
from Mar. 2025 (72.26) to Mar. 2026 (69.80).
It may suggest that Danaheraccelerated paying its suppliers.
Danaher Days Payable Related Terms
Danaher Days Payable Historical Data
* Premium members only.
The historical data trend for Danaher's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Danaher's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Danaher Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Danaher's Days Payable distribution charts can be found below:
* The bar in red indicates where Danaher's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Danaher's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Danaher (FRA:DAP) has a Days Payable of 69.80 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Danaher and its competitors. This is near median its historical median of 69.44. Over the past decade, Danaher's Days Payable has ranged from 62.98 to 88.13. According to the industry distribution chart, Danaher ranks #100 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 52.6%.
Is Danaher's Days Payable too high?
Danaher's current Days Payable of 69.80 is near median its 10-year median of 69.44. Over the past 10 years, this metric has ranged from a low of 62.98 to a high of 88.13. The Medical Diagnostics & Research industry median Days Payable is 67.28. Danaher's value of 69.80 is 3.8% above this industry median. Based on the distribution chart, Danaher ranks #100 out of 190 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Danaher has a GF Score™ of 72/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Danaher's Days Payable compare to TMO and IDXX?
According to the Medical Diagnostics & Research industry distribution chart, Danaher ranks #100 out of 190 companies for Days Payable. This places Danaher in the lower half of its industry. The industry median Days Payable is 67.28. Danaher's value of 69.80 is 3.8% above this benchmark. Historically, Danaher's own Days Payable has ranged from 62.98 to 88.13 over the past decade. While the company's 10-year median is 69.44 vs. the industry median of 67.28, Danaher has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Danaher's current Days Payable of 69.80 is 3.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Danaher and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Danaher's current Days Payable is 69.80, which is near median its own 10-year median of 69.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Danaher stock overvalued right now?
Based on GuruFocus' analysis, Danaher (FRA:DAP) is currently considered Modestly Undervalued. The stock's GF Value™ is €204.24, compared to a current price of €169.05 — trading 17.2% below its estimated fair value. The current Days Payable is 69.80, which is near median its 10-year median of 69.44 and 3.8% above the Medical Diagnostics & Research industry median of 67.28. Danaher's overall GF Score™ is 72/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Danaher (FRA:DAP), the current Days Payable is 69.80 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Danaher (FRA:DAP) Overvalued in 2026?
Based on GuruFocus' analysis, Danaher stock appears to be undervalued.
The current stock price of €169.05 is trading 17.2% below its estimated GF Value™ of €204.24.
GuruFocus considers Danaher to be Modestly Undervalued.
Key valuation signals for FRA:DAP:
Days Payable: 69.80 (near median its 10-year median of 69.44)
GF Value™: €204.24 vs. price of €169.05 (17.2% below fair value)
Industry Position: 3.8% above the Medical Diagnostics & Research median (#100 of 190)
No single metric tells the full story. See the FRA:DAP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Then, through a series of mergers, acquisitions, and divestitures, Danaher now focuses primarily on manufacturing scientific instruments and consumables in the life sciences and diagnostic industries after the late 2023 divestiture of its environmental and applied solutions group, Veralto.
72GF Score
Get the complete analysis for FRA:DAP
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:DAP has been successfully added to your 
